|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
8/12/2009 10:46:12 AM
Auckland, New Zealand, 12 August 2009 – Genesis Research and Development Corporation Ltd (NZSX/ASX: GEN) today confirmed that the Share Purchase Plan (SPP) which closed on 11 August has been oversubscribed. Total subscriptions were received under the SPP for 10,716,574 shares (NZ$643,000). The maximum number of shares available for subscription under the SPP was 7,838,040 shares (NZ$470,282.40). Accordingly, the SPP was oversubscribed by 37%. All applications will be reduced on a pro rata basis.
The NZSX Listing Rules limit the number of shares that can be issued under the SPP to 30% of the number of shares on issue prior to the SPP, which amounts to 7,838,040 shares (NZ$470,282 at the issue price of $0.06 per share). Shares will be issued and allotted on or about Friday, 14 August 2009, and the excess subscriptions of NZ$172,718 will be refunded to applicants. The holding statements / confirmation advice and the refund cheques will be posted before the end of next week (by close of business Friday, 21 August 2009).
Genesis Chief Executive, Stephen Hall, said, "It is very pleasing to see the level of support from shareholders. The funds raised will be used to support the gene silencing programme."
|
|
|
|
|
|
|
|
|
|
|